All-trans retinoic acid (ATRA), a pan-retinoic acid receptor (RAR) agonist, is, along with other retinoids, a promising therapeutic agent for the treatment of a variety of solid tumors. On the one hand, preclinical studies have shown promising anticancer effects of ATRA in breast cancer; on the other hand, resistances occurred. Autophagy is a cellular recycling process that allows the degradation of bulk cellular contents. Tumor cells may take advantage of autophagy to cope with stress caused by anticancer drugs. We therefore wondered if autophagy is activated by ATRA in mammary tumor cells and if modulation of autophagy might be a potential novel treatment strategy. Indeed, ATRA induces autophagic flux in ATRA-sensitive but not in ATRA-resistant human breast cancer cells. Moreover, using different RAR agonists as well as RARα-knockdown breast cancer cells, we demonstrate that autophagy is dependent on RARα activation. Interestingly, inhibition of autophagy in breast cancer cells by either genetic or pharmacological approaches resulted in significantly increased apoptosis under ATRA treatment and attenuated epithelial differentiation. In summary, our findings demonstrate that ATRA-induced autophagy is mediated by RARα in breast cancer cells. Furthermore, inhibition of autophagy results in enhanced apoptosis. This points to a potential novel treatment strategy for a selected group of breast cancer patients where ATRA and autophagy inhibitors are applied simultaneously. Cell Death and Disease (2015) 6, e1861; doi:10.1038/cddis.2015.236; published online 27 August 2015
Macroautophagy (hereafter referred to as autophagy) is a conserved mechanism characterized by the formation of double-membrane structures. These so-called autophagosomes deliver cytoplasmic material to the lysosome for subsequent degradation. 1 Basal autophagy requires tight regulation as alterations in autophagy have been associated with many pathological conditions, including cancer. 2 In addition, autophagy has been linked to fundamental processes such as development and cellular differentiation. In these processes, autophagy contributes to cell remodeling as observed during erythrocyte, lymphocyte or adipocyte differentiation. 3 In the context of cancer and cancer therapy, autophagy is a double-edged sword. Owing to its homeostatic role in the removal of potentially harmful damaged organelles and protein aggregates, it is suggested to be tumor suppressive under normal conditions. 4 In cancer cells, however, autophagy can be oncogenic, enabling survival under stressful conditions. 5 Hence, the role of autophagy in tumorigenesis is clearly dependent on the cellular context and the tumor stage. In some cases, therapeutic agents induce an autophagic response that can promote resistance to treatment. In other cases, autophagy contributes to the action of antitumor agents. 6 Therefore, knowledge about the action exerted by autophagy in response to anticancer treatments is a prerequisite for the identification of patients benefiting from therapeutic strategies based on autophagy modulators.
All-trans retinoic acid (ATRA), the active metabolite of vitamin A, exerts diverse functions in almost every cell and organ system. ATRA controls cell proliferation, differentiation as well as immune, and neuronal functions primarily via regulation of gene expression. 7 Endogenous retinoid levels are altered in different diseases of the lung, kidney and central nervous system, and contribute to their pathophysiology. 8 ATRA is successfully used in the treatment of acute promyelocytic leukemia (APL), where it induces granulocytic differentiation of the blast and subsequent cell death of the differentiated leukemic cells. Importantly, ATRA-induced differentiation of the APL cell line, NB4, involves induction of macroautophagy. [9] [10] [11] [12] In addition to its cytodifferentiating capacity in APL, ATRA has been proposed as an antitumorigenic agent for other types of cancer. The antiproliferative, cytodifferentiating and proapoptotic effects of retinoids are predominantly mediated by the nuclear hormone retinoid acid receptors RARα, RARβ and RARγ. 13, 14 In breast cancer, preclinical studies have shown that retinoids are promising therapeutic agents. However, the clinical trials conducted so far were somewhat disappointing, possibly as a consequence of the study designs. 15 Breast cancer is a highly 1 heterogeneous disease represented as a collection of diseases with distinct histopathological and molecular features. The most important clinical classification of this tumor is based on the determination of ER (estrogen receptor), PR (progesterone receptor) and HER2 (human epidermal growth factor receptor-2) receptors. ER-positive breast cancer patients are eligible for hormonal therapies, whereas HER2 oncogenic activity can be blocked using targeted therapies.
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Approximately 15-20% of breast carcinomas overexpress HER2, which is associated with poor prognosis. 17 Owing to the development of resistance to current HER2-targeted treatments such as trastuzumab and lapatinib alternative therapeutic strategies are required. 18, 19 ATRA was recently shown to exert strong antitumor activity in cell lines representing a subgroup of HER2-positive breast tumors characterized by coamplification of the ERBB2 and RARα genes. 20 This antitumor activity is remarkably stimulated by simultaneous HER2 inhibition with lapatinib. In addition, autophagy is induced upon ATRA treatment of the APL-derived cell line NB4 [9] [10] [11] and retinoids have clinical relevance in breast cancer. Thus, we investigated whether and how autophagy is induced in breast cancer cells. In addition, we evaluated whether autophagy modulation represents a potential therapeutic strategy for potentiating ATRA cytotoxicity in breast cancer cells.
Results
ATRA initiates a dose-and time-dependent autophagic response associated with epithelial differentiation in SKBR3 cells. To determine whether ATRA modulates autophagy in breast cancer cells, we first measured steadystate levels of the autophagy marker LC3B-II in the two luminal, HER2-positive ER-negative breast cancer cell lines, SKBR3 (HER2/RARα coamplification) and MDA-MB453 (HER2 amplification), upon challenge with different concentrations of ATRA during different time periods. We chose these two cell lines as SKBR3 are sensitive to and MDA-MB453 cells are resistant to ATRA. 20 In the SKBR3 cells, we observed a dose-dependent increase in the steadystate levels of lipidated LC3B (LC3B-II), which was paralleled by induction of the differentiation-associated β-catenin protein. These effects were not observed in ATRA-treated MDA-MB453 cells (Figures 1a and b) . ATRA-dependent cytodifferentiation was further visualized at day 2, using immunofluorescence microscopy to highlight the redistribution of β-catenin to the cell membrane where it contributes to epithelial differentiation. 20 ATRA treatment of SKBR3 clearly caused relocalization of β-catenin to the cell membrane. Regardless of ATRA treatment, MDA-MB453 cells showed a punctuated perinuclear distribution with no membrane localization of β-catenin 20 ( Figure 1c ). To further quantify autophagy induction in our cell line models, we determined endogenous LC3B puncta by confocal microscopy. We observed a significant increase in endogenous LC3B puncta in SKBR3 but not in MDA-MB453 cells (Figure 1d and Supplementary figure 1a) . Given the significant induction of LC3B-II (Figures 1a and b) , we next monitored autophagic flux to exclude that a block in the autophagy pathway causes LC3B-II accumulation. We therefore quantified lipidated LC3B levels in the presence and absence of a saturating lysosomal inhibitor, bafilomycin A1 (BafA). ATRAinduced LC3B lipidation, which was significantly enhanced in the presence of BafA, suggests increased autophagic flux. In contrast, ATRA administration did not result in a further increase beyond basal autophagy levels in the MDA-MB453 cell line (Figure 1e ). As autophagy must be evaluated using different techniques, 21 we also used a standard biochemical method to determine autophagic activity. We measured the turnover of long-lived 14 C-valine-labeled proteins upon 2 days of ATRA treatment of SKBR3 and MDA-MB453 cells in the presence or absence of the autophagy inhibitor BafA. In SKBR3 cells, the proteolysis of long-lived proteins was significantly increased by ATRA, whereas no such increase was observed in MDA-MB453 cells (Figure 1f ). Moreover, 3-methyladenine (3-MA) blocked ATRA-mediated autophagy as efficiently as BafA, indicating that retinoids preferentially induce macroautophagy in retinoid-sensitive breast cancer cells ( Figure 1g ). As a third assay to assess autophagic flux in our breast cancer cells, we took advantage of a Cherry-GFP-LC3B tandem construct. As the GFP signal is quenched at low pH, this system allows to distinguish between autophagosomes (Cherry + /GFP + ) and autolysosomes (Cherry ATRA-induced autophagy flux depends on RARα. As we observed increased autophagic flux only in ATRA-sensitive cells, we were interested in the signal-transduction mechanism leading to the observed phenotype. We focused on the main retinoic acid effectors, that are, the nuclear retinoid receptors, RARα, RARβ and RARγ. To this end, we treated SKBR3 cells with RARα, RARβ and RARγ agonists alone and in combination with BafA and determined LC3B puncta formation (Figures 3a and b To validate the LC3B immunofluorescence data, we additionally performed long-lived protein degradation assays. In agreement with the immunofluorescence data, only the specific RARα agonist, AM580, significantly increased autophagic-dependent degradation of 14 C-valine-labeled proteins ( Figure 3d ). As a third method to determine autophagic flux, LC3B-II western blot was performed (Figures 3e and f) . Again, increased autophagic flux was seen only upon RARα but not upon RARβ or RARγ activation (Figures 3e and f) . These results reinforce the notion that RARα is the limiting nuclear receptor in the induction of autophagic flux by retinoic acid. It is worth mentioning that autophagy induction by AM580 was paralleled by induction of the differentiation markers β-catenin and VE-cadherin ( Figure 3e ). To support our hypothesis that autophagy is mediated by RARα, we depleted RARα in SKBR3 cells. As observed by Bosh et al., 13 knocking down RARα changed the cell morphology to a spindle-like shape (data not shown). Depletion of RARα prevented the ATRA-dependent increase in β-catenin and VE-cadherin, confirming that RARα activation is key to cytodifferentiation (Figure 4a) . 20 In addition, ATRA-dependent cell membrane relocalization of β-catenin observed in control transduced cells was reduced in SKBR3 RARα knockdown cells (Figure 4b ). Although RARα depletion did not affect the basal autophagy levels, it significantly blocked LC3B mRNA induction as well as LC3B-II turnover following ATRA treatment (Figures 4c and d ). Finally, RARα depletion significantly decreased BafA-and 3-MA-dependent degradation of long-lived proteins in ATRAtreated cells (Figure 4e ). Taken together, these results strongly suggest that ATRA-induced autophagy is mediated by RARα.
ATG gene depletion or chloroquine-mediated autophagy inhibition enhances apoptosis in ATRA-treated SKBR3 cells. The antitumor effects of ATRA on SKBR3 cells are mainly the result of a growth inhibitory and cytodifferentiating response with subsequent induction of apoptosis. 20 Indeed, we found a time-and dose-dependent increase in caspase-3 cleavage in SKBR3 but not in MDA-MB-453 cells treated with ATRA ( Figure 5a and Supplementary Figure 2a) . To evaluate whether depletion of key autophagy genes affects ATRAinduced cell death, we first silenced ATG7 in SKBR3 and MDA-MB453 cells. Control and ATG7-depleted cells were subjected to ATRA treatment before apoptosis was determined at different time points using multiple assays. In SKBR3 cells, knocking down ATG7 clearly enhanced ATRA- Figures 5b and c) . In contrast, no induction of cleaved caspase-3 was evident in either control or ATG7-silenced MDA-MB453 cells (Figure 4b , right panel). ATG7-knockdown efficiency was evaluated by western blotting (Figure 5d ). In agreement with the western blot results, caspase-3/7 activity was significantly enhanced in ATRA-treated SKBR3 ATG7-knockdown cells, whereas silencing ATG7 in MDA-MB453 cells did not affect this enzymatic activity (Figure 5e ). Increased Annexin V/PI staining in ATG7-depleted SKBR3 cells as compared with control cells validated our previous observations (Figure 5f ). The high sensitivity of the Annexin V assay allowed the detection of increased basal levels of apoptosis even in untreated SKBR3 ATG7-depleted cells, although not statistically significant. Based on our findings above that RARα is (e) Western blot analysis for VE-cadherin, β-catenin and LC3B of SKBR3 cells treated as in (a). (f) LC3B-II levels on western blot were normalized to GAPDH and quantified from at least five independent experiments using the ImageJ software (NIH, Bethesda, MD, USA). LC3B-II levels of control treated cells were arbitrarily set to 100%. Mann-Whitney U-test: *Po0.05, **Po0.01 and ****Po0.0001
Retinoid-induced autophagy in breast cancer cells D Brigger et al key in activating the autophagic flux, we repeated our experiments in ATG7-knockdown and control SKBR3 cells using the RARα agonist AM580. As observed with ATRA, silencing ATG7 significantly enhanced AM580-induced SKBR3 cell death (Supplementary Figures 2b and c) . To support our findings with SKBR3 ATG7-knockdown cells above, we silenced two additional ATG genes, ATG5 and the class III phosphatidylinositol 3-kinase VPS34 in these cells. Following ATRA treatment, ATG5 and VPS34 depletion led to a consistent and significant increase in SKBR3 caspase-3/7 activity as compared with scramble control transfected cells (Figure 5g ). Knockdown efficiencies for ATG5 and VPS34 are shown in Supplementary Figure 2d . This increased cell death response was paralleled by attenuated activation of autophagy as assessed by WIPI1 transcript levels (Supplementary Figure 2e) . 23 Finally, we evaluated the action of chloroquine, a clinically relevant autophagy inhibitor, on SKBR3 cells exposed to ATRA. We observed no marked increase in cell death when SKBR3 cells were treated with chloroquine alone, but in combination with ATRA, a significant increase in cell death compared with that in cells treated with ATRA alone was seen (Figure 5h ).
As induction of autophagy was paralleled by epithelial differentiation (Figures 1a and 3d ), we were asking whether inhibition of autophagy would impact on differentiation. To this end, we treated SKBR3 cells with ATRA, chloroquine or a combination thereof for 4 days and determined the expression of the differentiation markers VE-cadherin and β-catenin by western blotting. Blocking autophagy markedly attenuated epithelial differentiation (Figure 6a-d) . Whereas the effects of autophagy inhibition on β-catenin levels, although significant, were rather modest (Figure 6b, left panel) , the impact on VE-cadherin were more pronounced at least when cells were treated with ATRA and 20 μM chloroquine (Figure 6b, right  panel) . Similarly, depletion of ATG7 significantly decreased ATRA-induced epithelial differentiation of SKBR3 cells (Figures 6c and d) . Interestingly, steady-state levels of β-catenin and VE-cadherin were increased in ATG7-depleted cells, although the effect is not statistically significant.
In conclusion, our results demonstrate that inhibition of autophagy either by pharmacological or genetic means significantly increases ATRA-mediated cell death in retinoidsensitive SKBR3 cells and lowers epithelial differentiation.
Discussion
In the present study, we report that ATRA induces autophagic flux in retinoid-sensitive SKBR3 breast cancer cells via RARα. In contrast, autophagy activation is not observed in the retinoid-resistant MDA-MB453 cell line. Using 3-MA as a specific inhibitor of macroautophagy, 21 we were able for the first time to directly link macroautophagy induction to RARα activation in breast cancer cell lines. We hypothesize that ATRA induces autophagy only in breast cancer cells that are not terminally differentiated and can be differentiated by retinoids for the following reasons: (1) selective activation of RARα by AM580 or ATRA is sufficient to induce both autophagy and cytodifferentiation 20 in SKBR3 cells, and (2) MDA-MB453 cells are resistant to ATRA-dependent autophagy and differentiation. In agreement with our hypothesis, ATRA causes autophagy in differentiating AML cells. [9] [10] [11] [12] Additionally, NB4-resistant cells (NB4-R2), which are unable to differentiate upon ATRA administration, do not show an autophagic response to retinoids. 11 A study by Anguiano et al. 24 demonstrated that ATRA does not promote macroautophagy in mouse fibroblasts, although RARα knockdown decreased macroautophagy under basal conditions in these terminally differentiated cells. In contrast to their study, where depleting RARα induced 3-MA-sensitive autophagy, our results in differentiation-competent breast cancer cells show that RARα depletion abrogates 3-MA-sensitive proteolysis. Work performed in HeLa cells, a cell type that cannot be further differentiated with ATRA, indicated that retinoic acids promote autophagosome maturation through a pathway that does not involve the classic nuclear retinoid receptor pathway. 25 This further supports our hypothesis that RARs are particularly important for retinoid-mediated autophagy induction in non-terminally differentiated cells.
A novel treatment strategy for breast cancer may involve combinations of retinoids and autophagy inhibitors with the aim of shortening the survival of breast cancer cells. Several groups identified a role for autophagy in response to anticancer therapy, for example, camptothecin activates auto- phagy, which in turn delays apoptotic cell death in noninvasive breast cancer. 26 Somewhat conflicting data exist on the role of autophagy activation during HER2-targeted therapy with lapatinib. On the one hand, combining lapatinib with a pharmacological inhibitor of autophagy resulted in reduced cell death, 27 whereas on the other blocking autophagy by beclin-1 depletion potentiated the therapeutic efficiency of lapatinib. 28 Furthermore, inhibition of epirubicin-triggered autophagy enhances therapeutic efficiency in MDA-MB-231 breast cancer cells. 29 Given the possible role for autophagy as therapeutic strategy, it is crucial to emphasize that different stress inducers lead either to a cytoprotective or cytotoxic autophagy response. The outcome is clearly dependent on the stage and type of tumor. 30 These findings underline the importance to evaluate the tumor response to autophagy individually for each type of cancer and therapy condition. Our results clearly support a model where blocking autophagy by genetic and pharmacological means greatly improves ATRA toxicity in SKBR3 cells. Therefore, it is tempting to speculate that ATRA-induced autophagy is cytoprotective in our cell line model. However, careful interpretation of these results is warranted, as one of our cell death assays showed enhanced basal levels of apoptosis in control treated SKBR3 cells. We cannot finally exclude that SKBR3 cells are highly sensitive to autophagy inhibition irrespective of ATRA treatment. Another explanation might be that physiological concentrations of ATRA, present in the fetal bovine serum (FBS), are sufficient to induce some degree of cell death upon autophagy inhibition. The exact mechanism how blocking autophagy contributes to cell death in ATRA-sensitive breast cancer cells remains to be elucidated.
Autophagy and cellular differentiation have been linked earlier, for example, during the last step of reticulocyte maturation, all membrane-bound organelles and ribosomes are removed to ensure optimal hemoglobin production and oxygen transport. 31 Autophagy has been shown to contribute to the elimination of mitochondria in this step. [32] [33] [34] Similarly, adipocytes induce autophagy, which is important for the remodeling process. 3 Furthermore, ATG5 is crucial for the transition from the pro-to the pre-B-cell stage, 35 and monocyte differentiation is accompanied by autophagy induction. 36, 37 Strategies aiming at the reactivation of differentiation programs in the stem cell compartment of solid tumors have great therapeutic potential. 38 For example, CD44 inhibition in breast cancer stem cells results in differentiation and enhanced drug sensitivity. 39 Similarly, ATRA-dependent differentiation of cancer stem cells reduces the formation of mammospheres and the tumor-initiating potential of certain breast cancer cell lines. 40 We now show that autophagy once activated supports epithelial differentiation, as assessed by β-catenin and VE-cadherin expression. These markers are significantly downregulated upon inhibition of autophagy. In this regard, autophagy inhibition as suggested above seems to be rather disadvantageous, as it decreases the effects of ATRA on differentiation. Nevertheless, the negative effect of blocking autophagy on differentiation might be negligible given the benefits of highly increased cell death when these two treatments are combined. 
